Investment & Fund Management

Minoryx Therapeutics, a biotech company based in Spain, is dedicated to developing innovative therapies for rare diseases, particularly adrenoleukodystrophy (ALD), a genetic condition that can lead to severe health issues and currently has no cure. Founded in 2015, Minoryx faced significant challenges in funding and advancing their research to address the high unmet medical needs associated with ALD and other rare genetic disorders.

To overcome these challenges, Minoryx secured investment from Ysios Capital, a venture capital firm supported by the European Investment Fund (EIF) under the EU’s Investment Plan for Europe. This tailored financial support enabled Minoryx to initiate regulatory pre-clinical activities and successfully complete a phase-1 clinical trial. The investment not only facilitated the company's growth—allowing them to double their size—but also positively impacted various service providers involved in their clinical studies, regulatory processes, and manufacturing.

As a result of this funding, Minoryx is now progressing towards further clinical trials with the aim of obtaining marketing authorization for their therapies. The investment has positioned Minoryx to continue its mission of developing treatments for ALD and to explore potential applications for other rare diseases, thereby contributing significantly to the life sciences sector and improving patient outcomes in this critical area.